Domestic pharmaceutical industry faces an estimated combined revenue loss of around Rs 641 crore after move by the National Pharmaceutical Pricing Authority (NPPA) to bring 108 formulation packs of medicines under price control. Sanofi India, which has a large portfolio of diabetes and heart disease medicine in the local market, may face a revenue loss of around Rs 139 crore.